OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ was granted by USPTO

1.Date of occurrence of the event:2022/10/13 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:OBI Pharma Inc. was informed by the patent office that patent for OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ has been granted […]